Xolair in Patients With Chronic Sinusitis

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00117611
Phase
PHASE4
Status
Completed

Conditions

  • Sinusitis

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.

Key Dates

Start date
Jul 31, 2005
Status verified
Sep 2013
Primary completion
May 31, 2007
Completion
Jan 31, 2009

Study Design

Enrollment
14 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
  • Placebo Comparator: 2
    placebo administered subcutaneously once or twice monthly

Primary Outcome Measure

Mucosal thickness on CT scan [ Time Frame: after 6 months of treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
The University of ChicagoChicagoIllinois60637-

Find similar trials in Chicago, IL

By research site
The University of Chicago· Chicago, IL

Related Studies